Boston Scientific Corp. (NYSE: BSX) has seen a decline in its stock price by -0.93 in relation to its previous close of 68.07. However, the company has experienced a -1.82% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-10 that With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.
Is It Worth Investing in Boston Scientific Corp. (NYSE: BSX) Right Now?
The price-to-earnings ratio for Boston Scientific Corp. (NYSE: BSX) is above average at 63.01x, Company’s 36-month beta value is 0.79.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 10 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for BSX is 1.46B, and currently, short sellers hold a 0.85% ratio of that floaft. The average trading volume of BSX on April 16, 2024 was 6.42M shares.
BSX’s Market Performance
BSX’s stock has seen a -1.82% decrease for the week, with a 0.87% rise in the past month and a 12.51% gain in the past quarter. The volatility ratio for the week is 1.43%, and the volatility levels for the past 30 days are at 1.32% for Boston Scientific Corp. The simple moving average for the past 20 days is -0.76% for BSX’s stock, with a 17.98% simple moving average for the past 200 days.
Analysts’ Opinion of BSX
Many brokerage firms have already submitted their reports for BSX stocks, with Mizuho repeating the rating for BSX by listing it as a “Buy.” The predicted price for BSX in the upcoming period, according to Mizuho is $80 based on the research report published on February 01, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see BSX reach a price target of $59. The rating they have provided for BSX stocks is “Outperform” according to the report published on July 19th, 2023.
CL King gave a rating of “Buy” to BSX, setting the target price at $64 in the report published on June 30th of the previous year.
BSX Trading at 0.83% from the 50-Day Moving Average
After a stumble in the market that brought BSX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.56% of loss for the given period.
Volatility was left at 1.32%, however, over the last 30 days, the volatility rate increased by 1.43%, as shares surge +1.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.04% upper at present.
During the last 5 trading sessions, BSX fell by -1.82%, which changed the moving average for the period of 200-days by +26.17% in comparison to the 20-day moving average, which settled at $68.02. In addition, Boston Scientific Corp. saw 16.66% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BSX starting from Sorenson John Bradley, who sale 16,351 shares at the price of $69.30 back on Apr 01 ’24. After this action, Sorenson John Bradley now owns 50,638 shares of Boston Scientific Corp., valued at $1,133,069 using the latest closing price.
Carruthers Wendy, the EVP, Human Resources of Boston Scientific Corp., sale 6,983 shares at $68.42 during a trade that took place back on Apr 01 ’24, which means that Carruthers Wendy is holding 51,068 shares at $477,777 based on the most recent closing price.
Stock Fundamentals for BSX
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.69 for the gross margin
The net margin for Boston Scientific Corp. stands at 0.11. The total capital return value is set at 0.08. Equity return is now at value 8.64, with 4.71 for asset returns.
Based on Boston Scientific Corp. (BSX), the company’s capital structure generated 0.33 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.49. The interest coverage ratio of the stock is 8.81.
Currently, EBITDA for the company is 3.62 billion with net debt to EBITDA at 2.57. When we switch over and look at the enterprise to sales, we see a ratio of 7.57. The receivables turnover for the company is 6.39for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.32.
Conclusion
In a nutshell, Boston Scientific Corp. (BSX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
